CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
08 6월 2024 - 4:32AM
A release was issued under a similar headline on
Thursday, June 6th by Tevogen Bio Holdings Inc. (Nasdaq: TVGN).
Please note that the second paragraph has been corrected and a
photo is now included. The corrected release follows:
Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq:
TVGN), is a clinical-stage specialty immunotherapy company
harnessing one of nature’s most powerful immunological weapons,
CD8+ cytotoxic T lymphocytes (“CD8+ CTLs”), to develop
off-the-shelf, precision T cell therapies for the treatment of
infectious diseases, cancers, and neurological disorders with the
aim of addressing the significant unmet needs of large patient
populations.
Tevogen Bio, founded by a group of pioneering industry leaders
and distinguished scientists with extensive drug development and
global product launch experience, aims to chart the next frontier
of medicine, where disruptive science and innovative business
models pave the way to a healthier future for all, centered on the
concept that sustainable business success is intrinsically linked
to societal prosperity. At its inaugural post-public listing social
engagement on May 31, 2024, Tevogen's leadership gathered with
Victor Sordillo (Mayor, Warren Twp. NJ), Lisa Lontai (Deputy Mayor,
Warren Twp. NJ), Raymond Giacobbe (Mayor, Rahway NJ), Matthew
Moench (Mayor, Bridgewater NJ), Andrew McNally (Mayor, Bernards
NJ), Robert Parisi (Former Mayor, West Orange NJ), Tammy Williams
(Councilwoman, West Orange NJ), Sara Sooy (Commissioner Deputy
Director, Somerset County NJ), Douglas Singleterry (Commissioner of
Somerset County), and Honorable U.S. Congressmen Josh Gottheimer
and Robert Menendez. The event also included the nation’s first
responders including Matthew Caliente (President of Professional
Firefighters Association of New Jersey and Long COVID patient
advocate) and Robert Ferreiro (Warren Twp. Chief of Police) aiming
to understand patients' needs and discuss how the Tevogen model
could reduce healthcare costs and improve patient outcomes.
"We are honored by the widespread interest in Tevogen's business
model from all sectors of society and express our gratitude to all
attendees, especially the patients who shared their stories,"
remarked Dr. Ryan Saadi, founding CEO of Tevogen Bio.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company
harnessing one of nature’s most powerful immunological weapons,
CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically
unmodified precision T cell therapies for the treatment of
infectious diseases, cancers, and neurological disorders, aiming to
address the significant unmet needs of large patient populations.
Tevogen Leadership believes that sustainability and commercial
success in the current era of healthcare rely on ensuring patient
accessibility through advanced science and innovative business
models. Tevogen has reported positive safety data from its
proof-of-concept clinical trial, and its key intellectual property
assets are wholly owned by the company, not subject to any
third-party licensing agreements. These assets include three
granted patents and twelve pending patents, two of which are
related to artificial intelligence.
Contacts
Tevogen Bio CommunicationsT: 1-877-TEVOGEN, Ext-701
Communications@Tevogen.com
Photo: https://www.globenewswire.com/NewsRoom/AttachmentNg/3acdaab4-dbc7-4635-8017-47fa52389a44
Tevogen Bio (NASDAQ:TVGNW)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Tevogen Bio (NASDAQ:TVGNW)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024